The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.
 
Elizabeth R. Plimack
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Aveo; Bristol-Myers Squibb/Medarex; Calithera Biosciences; Calithera Biosciences; Genentech; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; Pfizer; Pfizer; Regeneron; Seagen
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Catherine Tangen
No Relationships to Disclose
 
Melissa Plets
No Relationships to Disclose
 
Rutika Kokate
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Eric A. Ross
Stock and Other Ownership Interests - Procter & Gamble
Patents, Royalties, Other Intellectual Property - Method for Screening Muscle Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy Responsiveness (Inst)
 
Erin Grundy
No Relationships to Disclose
 
Woonyoung Choi
No Relationships to Disclose
 
Colin P.N. Dinney
Consulting or Advisory Role - FKD Therapies; NCI; The University of Eastern Finland, Faculty of Health Sciences (UEFHS)
Research Funding - FKD Therapies; Merck; NCI; University of Eastern Finland (Inst)
 
I-Ling C. Lee
No Relationships to Disclose
 
Scott Lucia
No Relationships to Disclose
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
David James McConkey
Honoraria - BioClin Therapeutics; H3 Biomedicine; Janssen Oncology
Research Funding - AstraZeneca; BioClin Therapeutics
Travel, Accommodations, Expenses - BioClin Therapeutics; H3 Biomedicine